Formulation and in vitro assessment of sustained release terbutaline sulfate tablet made from binary hydrophilic polymer mixtures

Pharmaceutical Development and Technology

Volumn 18, Issue 5, 2013, Pages 1204-1212

  Al Akayleh, Faisal ^a   Remawi, Mayyas Al ^b   Rashid, Iyad ^c   Badwan, Adnan ^c  

^a UNIVERSITY OF PETRA   (Jordan)

^b TAIF UNIVERSITY   (Saudi Arabia)

^c JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

Author keywords

Chitosan; Scale up; Sustained release matrix system; Terbutaline sulfate; Xanthan gum

Indexed keywords

BICARBONATE; CHITOSAN; POLYMER; TERBUTALINE; TERBUTALINE SULFATE; TST 0602018; UNCLASSIFIED DRUG; XANTHAN;

ARTICLE; BIOCOMPATIBILITY; COMPRESSION; DISSOLUTION; DRUG FORMULATION; MATRIX TABLET; PARTICLE SIZE; PRIORITY JOURNAL; SCALE UP; SUSTAINED DRUG RELEASE; THERMOGRAPHY; VISCOSITY;

CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DELAYED-ACTION PREPARATIONS; DIFFUSION; DRUG COMPOUNDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PARTICLE SIZE; POLYMERS; POLYSACCHARIDES, BACTERIAL; SODIUM BICARBONATE; SOLUBILITY; TABLETS; TERBUTALINE;

EID: 84887497088     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2011.620968     Document Type: Article

References (25)

1. Leon Shargel, Izzy Kanfer. (2005). Generic drug product development-solid oral dosage forms. In: Leon Shargel and Izzy Kanfer (eds). Introduction to Generic drug development. Chapter 1. N.Y. USA:Marcel Dekker Inc. p 1-3.
2. Abdelbary GA, Tadros MI. Design and in vitro/in vivo evaluation of novel nicorandil extended release matrix tablets based on hydrophilic interpolymer complexes and a hydrophobic waxy polymer. Eur J Pharm Biopharm 2008;69:1019-1028.
3. Varshosaz J, Tavakoli N, Kheirolahi F. Use of hydrophilic natural gums in formulation of sustained-release matrix tablets of tramadol hydrochloride. AAPS PharmSciTech 2006, 7: Article 24
4. Taludar M, Michoel A, Rombaut P, Kinget R. Comparative study on xanthan gum and hydroxypropylmethylcellulose as matrices for controlled-release drug delivery 1. Compaction and in vitro drug release behavior. Int J Pharmaceut1996; 129: 233-241.
5. Phaechamud T, Ritthidej GC. Sustained-release from layered matrix system comprising chitosan and xanthan gum. Drug Dev Ind Pharm 2007;33:595-605.
6. Argin-Soysal S, Kofnas P, Martin Y. Effect of complexation conditions on xanthan-chitosan polyelectrolyte complex gels. Food Hydrocolloids 2009; 23: 202-209
7. Fukuda M, Peppas NA, McGinity JW. Properties of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int J Pharm 2006;310:90-100.
8. Gerrit Borchard. Chitosans for gene delivery. Adv Drug Deliv Rev 2001; 52: 145-150.
9. García-Ochoa F, Santos VE, Casas JA, Gómez E. Xanthan gum: production, recovery, and properties. Biotechnol Adv 2000;18:549-579.
10. Qin Y. Review, Alginate fbres: An overview of the production processes and applications in wound management. Polymer international 2008; 57: 171-180
11. Vendruscolo CW, Andreazza IF, Ganter JL, Ferrero C, Bresolin TM. Xanthan and galactomannan (from M. scabrella) matrix tablets for oral controlled delivery of theophylline. Int J Pharm 2005;296:1-11.
12. Taludar MM, Kinget R. Comparative study on xanthangum and hydroxypropylmethylcellulose as matrices for controlled-release drug delivery II. Drug difusion in hydrated matrices. Int J Pharm 1997; 151: 99-107.
13. Ahuja S, Ashman J. Terbutaline sulfate. In: Florey Ked. Analytical Profles of Drug Substances, Academic Press, 1990, 19, 603-625
14. Daraghmeh N, Al-Omari MM, Sara Z, Badwan AA, Jaber AM. Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC. J Pharm Biomed Anal 2002;29:927-937.
15. Paradeep M. Sathe Andre S. Raw, Larry A. Quaderkirk, Lawrence X. Yu and Ajaz, S Hussain. (2005).Generic drug product development-solid oral dosage forms. In: Leon Shargel and Izzy Kanfer eds.Drug Product Performance, in Vitro. Chapter 8, N.Y. USA: Marcel Dekker Inc., p 187-209.
16. Higuchi T. Mechanism of sustained-action medication. Teoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963;52:1145-1149.
17. Korsmeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA. Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35.
18. Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985;60:110-111.
19. Hixson AW, Crowell JH. Dependence of reaction velocity upon surface and agitation. Ind Eng Chem 1931; 23: 923-931.
20. Sujja-areevath J, Munday DL, Cox PJ, Khan KA. Relationship between swelling, erosion and drug release in hydrophillic natural gum mini-matrix formulations. Eur J Pharm Sci 1998;6:207-217.
21. Sriamornsak P, Tirawong N, Korkerd K. Swelling, erosion and release behavior of alginate-based matrix tablets. Eur J Pharm Biopharm 2007;66:435-450.
22. Chellat F, Tabrizian M, Dumitriu S, Chornet E, Magny P, Rivard CH et al. In vitro and in vivo biocompatibility of chitosan-xanthan polyionic complex. J Biomed Mater Res 2000;51:107-116.
23. Mitrevej A, Sinchaipanid N, Rungvejhavuttivittaya Y, Kositchaiyong V. Multiunit controlled-release diclofenac sodium capsules using complex of chitosan with sodium alginate or pectin. Pharm Dev Technol 2001;6:385-392.
24. Takahashi T, Takayama K, Machida Y, Nagai T. Characteristics of polyion complexes of chitosan with sodium alginate and sodium polyacrylate. Int J Pharm 1990; 61: 35-41
25. FDA, September 1997, Guidance for Industry: SUPAC-MR: Extended Release Oral Dosage Forms; Development, Evaluation, and Application of In Vitro/In Vivo Correlations.